TY - JOUR
T1 - Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics
AU - Italiano, Antoine
AU - Lagarde, Pauline
AU - Brulard, Céline
AU - Terrier, Philippe
AU - Laë, Marick
AU - Marques, Bernard
AU - Ranchere-Vince, Dominique
AU - Michels, Jean Jacques
AU - Trassard, Martine
AU - Cioffi, Angela
AU - Piperno-Neumann, Sophie
AU - Chevreau, Christine
AU - Blay, Jean Yves
AU - Delcambre, Corinne
AU - Isambert, Nicolas
AU - Penel, Nicolas
AU - Bay, Jacques Olivier
AU - Bonvalot, Sylvie
AU - Le Cesne, Axel
AU - Coindre, Jean Michel
AU - Chibon, Frédéric
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Purpose: Data about the prognostic factors of soft-tissue leiomyosarcomas and their correlation with molecular profile are limited. Experimental Design: From 1990 to 2010, 586 adult patients with a primary soft-tissue leiomyosarcoma were included in the French Sarcoma Group (GSF) database after surgery of the primary tumor. Multivariate analyses were conducted by Cox regression model in a backward stepwise procedure. Genetic profiling was conducted for 73 cases. Results: Median age was 59 years (range, 21-98 years). The median follow-up of patients alive was 46 months. The 5-year metastasis-free survival (MFS) rate was 51% (95% location and grade > I were independent adverse prognostic factors for MFS). The 5-year overall survival (OS) rate was 63% [95% confidence interval (CI), 59-67]. On multivariate analysis, age ≥ 60 years old, tumor size > 5 cm, deep location, and grade > I were independent adverse prognostic factors for OS. Molecular profiling identified specific clusters with activation of different biologic pathways: retroperitoneal leiomyosarcomas are characterized by overexpression of genes involved in muscle differentiation and nonretroperitoneal leiomyosarcomas characterized by overexpression of genes mainly involved in extracellular matrix, wounding, and adhesion pathways. The CINSARC signature but not comparative genomic hybridization (CGH) profiling was predictive of outcome. Conclusion: Soft-tissue leiomyosarcomas represent a heterogeneous group of tumors with at least two categories, retroperitoneal and extremities leiomyosarcomas, having specific clinical outcome and molecular features. Future clinical trials should consider this heterogeneity for a better stratification of patients.
AB - Purpose: Data about the prognostic factors of soft-tissue leiomyosarcomas and their correlation with molecular profile are limited. Experimental Design: From 1990 to 2010, 586 adult patients with a primary soft-tissue leiomyosarcoma were included in the French Sarcoma Group (GSF) database after surgery of the primary tumor. Multivariate analyses were conducted by Cox regression model in a backward stepwise procedure. Genetic profiling was conducted for 73 cases. Results: Median age was 59 years (range, 21-98 years). The median follow-up of patients alive was 46 months. The 5-year metastasis-free survival (MFS) rate was 51% (95% location and grade > I were independent adverse prognostic factors for MFS). The 5-year overall survival (OS) rate was 63% [95% confidence interval (CI), 59-67]. On multivariate analysis, age ≥ 60 years old, tumor size > 5 cm, deep location, and grade > I were independent adverse prognostic factors for OS. Molecular profiling identified specific clusters with activation of different biologic pathways: retroperitoneal leiomyosarcomas are characterized by overexpression of genes involved in muscle differentiation and nonretroperitoneal leiomyosarcomas characterized by overexpression of genes mainly involved in extracellular matrix, wounding, and adhesion pathways. The CINSARC signature but not comparative genomic hybridization (CGH) profiling was predictive of outcome. Conclusion: Soft-tissue leiomyosarcomas represent a heterogeneous group of tumors with at least two categories, retroperitoneal and extremities leiomyosarcomas, having specific clinical outcome and molecular features. Future clinical trials should consider this heterogeneity for a better stratification of patients.
UR - http://www.scopus.com/inward/record.url?scp=84874829740&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-2970
DO - 10.1158/1078-0432.CCR-12-2970
M3 - Article
C2 - 23329812
AN - SCOPUS:84874829740
SN - 1078-0432
VL - 19
SP - 1190
EP - 1196
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 5
ER -